Registrational Phase III AMPLIFY trial: Target number of participants achieved

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...
Seeking Alpha

Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences

SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...
Cure Today

FDA Approves Calquence Plus Venclexta for CLL and SLL

AMPLIFY showed improved PFS for acalabrutinib/venetoclax versus FCR or BR, with HR 0.65 and median PFS not estimable versus 47.6 months at 42.6-month follow-up ...
KTLA

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT

SYDNEY, May 29, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...
The Victoria Advocate

First patient imaged in Phase III AMPLIFY trial with 64Cu-SAR-bisPSMA PET/CT

The COBRA trial [2] that laid foundation for AMPLIFY in patients with BCR of prostate cancer showed that more lesions and more patients with a positive scan were identified on 64 Cu-SAR-bisPSMA ...